NCT01430169View on ClinicalTrials.gov

Pharmacokinetics of a Single Treatment Cycle of AA4500 0.58 mg in Men With Peyronie's Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

November 30, 2011

Study Completion Date

November 30, 2011

Conditions
Peyronie's Disease
Interventions
BIOLOGICAL

AA4500

Two injections of AA4500 0.58 mg 24 hours apart

Trial Locations (1)

91505

Martin Gelbard, MD Inc., Burbank

Sponsors
All Listed Sponsors
lead

Endo Pharmaceuticals

INDUSTRY